Stocks · Healthcare · Biotechnology
Genelux Corporation GNLX
$2.56 +1.59% Close, Oct 2, 2026 · NASDAQ · Market cap $114.8M
Weak trendExpensive vs sector
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 18.5% in a year.
- The stock is 69% below its highest close of the past year.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth, 3-year CAGRBottom 1%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 3%
- Gross marginBottom 1%
- Operating marginBottom 1%
- Accruals (lower is better)Top 7%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 21%
- Free-cash-flow yieldBottom 21%
- EBITDA / enterprise valueBottom 21%
- Sales / enterprise valueBottom 1%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 10%
- 6-month returnBottom 43%
- 1-year return vs S&P 500Bottom 14%
- Distance from 52-week highBottom 8%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 34%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 34%
- Upside to consensus price targetTop 3%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 48%
- Maximum drawdown, 3 yearsBottom 8%
- Beta vs S&P 500 (lower is better)Bottom 39%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Gross margin | -1762.5% | — | Bottom 1% | |
| Operating margin | -445200.0% | — | Bottom 1% | |
| Net margin | -422412.5% | — | — | |
| Free-cash-flow margin | -358537.5% | — | — | |
| Return on invested capital | -192.2% | — | Bottom 3% | |
| Revenue growth, 3-year CAGR | -91.0% | — | Bottom 1% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -32.5%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 88462.5%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -16.72%
- Shareholder yield
- -16.72%
- Share count change, 1 year
- +18.5%
- Share count change, 3-year CAGR
- +20.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -4.6%
- Average 2-day reaction, last 8
- -2.1%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $17.33
- Target vs current price
- +577.0%
- Analysts with a rating
- 3
- Share rating Buy or Strong Buy
- 67%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | -6.8% | -2.6% | -0.7% | -8.1% | — |
| May 7, 2026 | -11.1% | -1.4% | +11.1% | +7.3% | +3.8% |
| Mar 19, 2026 | -9.1% | -1.9% | +2.3% | +6.9% | +14.3% |
| Nov 5, 2025 | +8.7% | -3.3% | -26.3% | -42.7% | -66.3% |
| Aug 7, 2025 | +9.1% | -7.0% | -10.9% | -3.1% | +121.7% |
| May 6, 2025 | +12.5% | -7.2% | +10.8% | +2.4% | +35.1% |
| Mar 28, 2025 | -52.9% | +1.7% | -17.5% | -5.0% | -8.3% |
| Nov 14, 2024 | +0.0% | +4.6% | -11.4% | -10.3% | +99.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.21 | -$0.20 | -6.8% | — |
| May 7, 2026 | -$0.20 | -$0.18 | -11.1% | — |
| Mar 19, 2026 | -$0.24 | -$0.22 | -9.1% | $8,000 |
| Nov 5, 2025 | -$0.21 | -$0.23 | +8.7% | — |
| Aug 7, 2025 | -$0.20 | -$0.22 | +9.1% | — |
| May 6, 2025 | -$0.21 | -$0.24 | +12.5% | — |
| Mar 28, 2025 | -$0.26 | -$0.17 | -52.9% | $452,000 |
| Nov 14, 2024 | -$0.19 | -$0.19 | +0.0% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 13503.43× | — | — | Bottom 1% |
| Free-cash-flow yield | -24.99% | — | — | Bottom 21% |
| Earnings yield | -34.77% | — | — | Bottom 21% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -6.2%
- 200-day average slope (20 days)
- -7.5%
- Distance from 50-day average
- -3.1%
- Distance from 200-day average
- -9.9%
- RSI (14)
- 50.6
- Relative volume
- 1.09×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 54.7%
- Volatility vs own 5-year history
- 7th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.30
- Correlation with S&P 500
- 0.21
- Current drawdown from 1-year high
- -68.9%
- Maximum drawdown, 3 years
- -93.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jun 21, 2023 | Aug 5, 2024 | -95.7% | 282 days | Not yet recovered |
| Mar 6, 2023 | Mar 13, 2023 | -51.9% | 5 days | 7 days (Mar 22, 2023) |
| Mar 30, 2023 | May 15, 2023 | -24.6% | 31 days | 20 days (Jun 13, 2023) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $114.8M
- EPS, diluted (TTM)
- -$0.89
- Revenue (TTM)
- $8,000
- 52-week range
- $2.29 – $8.54
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $11.1M | $170,000 | $8,000 | $8,000 |
| Gross profit | -$895,000 | $10.1M | -$848,000 | -$895,000 | -$566,000 |
| Operating income | -$14.6M | -$3.0M | -$24.2M | -$31.7M | -$33.2M |
| Net income | -$17.8M | -$5.2M | -$28.3M | -$29.9M | -$32.1M |
| EPS (diluted) | -$0.69 | -$0.21 | -$1.16 | -$0.95 | -$0.86 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $8,000 | $0 | $0 |
| Net income | -$6.5M | -$9.0M | -$7.5M | -$7.5M | -$8.0M | -$9.2M | -$7.1M | -$9.5M |
| EPS (diluted) | -$0.19 | -$0.27 | -$0.21 | -$0.20 | -$0.21 | -$0.25 | -$0.22 | -$0.21 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$6.6M | -$3.6M | -$20.3M | -$21.2M | -$25.3M |
| Capital expenditure | $0 | -$49,000 | -$1.0M | -$381,000 | -$1.1M |
| Free cash flow | -$6.6M | -$3.6M | -$21.3M | -$21.6M | -$26.4M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $143,000 | $120,000 | $39.6M | $27.8M | $9.9M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $18.7M
- Total assets
- $26.2M
- Total liabilities
- $10.1M
- Total debt
- $2.4M
- Net debt
- -$6.8M
- Shareholders’ equity
- $16.1M
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 4,096,285
- Days to cover
- 14.41
- Change vs previous report
- +8.5%
FINRA short interest, settlement date Sep 15, 2026.